Atypical hemolytic uremic syndrome induced by CblC subtype of methylmalonic academia
Authors:
- Jieqiu ZhuangJZJieqiu Zhuang
- JianHuan YangJYJianHuan Yang
- Dexuan WangDWDexuan Wang
- Qing YangQYQing Yang
Open Access
- 1 October 2017
- journal article
- case report
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (43) , e8284
Abstract
Methylmalonic acidemia (MMA) is a common organic acidemia, mainly due to methylmalonyl-CoA mutase (MCM) or its coenzyme cobalamin (VitB12) metabolic disorders. Cobalamin C (CblC) type is the most frequent inborn error of cobalamin metabolism; it can develop symptoms in childhood and often combine multisystem damage, which leads to methylmalonic acid, propionic acid, methyl citrate, and other metabolites abnormal accumulation, causing nerve, liver, kidney, bone marrow, and other organ damage. A 4-year-old girl presented with paleness, fatigue, severe normochromic anemia, and acute kidney injury. Based on severe normochromic anemia and acute kidney injury, renal biopsy showed membranous proliferative glomerular lesions and thrombotic microvascular disease, supporting the diagnosis of aHUS. Although the serum vitamin B12 was normal, further investigation found the concentration of urinary methylmalonic acid and serum homocysteine increased obviously, genetic analysis revealed a heterozygous MMACHC mutation (exonl: c. 80A >G, c. 609G >A). The final diagnosis was aHUS induced by inherited methylmalonic acidemia (MMACHC heterozygous mutation exonl: c. 80A >G, c. 609G >A). The patient was treated with a 1mg vitamin B12 intramuscular injection daily for 4 days after which the dose was then adjusted to a 1mg intramuscular injection twice a week. At the same time, the girl was given levocarnitine, betaine, folic acid, along with supportive treatment. After treated by vitamin B12 for 10 days, the patient condition significantly improved, Follow-up results showed complete recovery of hemoglobin and renal function. Although the majority of MMA onset from neurological damage, our case illustrates that partial CblC-type MMA can onset with severe metabolic aHUS. On the basis of chronic thrombotic microangiopathy (TMA)-induced renal damage, it can be complicated by acute hemolytic lesions. MMA should be considered in those patients with unclear microangiopathic hemolytic anemia accompany significant megaloblastic degeneration in bone marrow. We should pay attention to the causes and adopt a reasonable treatment strategy.Keywords
This publication has 27 references indexed in Scilit:
- Globus pallidus involvement as initial presentation of methylmalonic acidemiaMovement Disorders, 2014
- Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and managementJournal of Inherited Metabolic Disease, 2011
- Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndromePediatric Nephrology, 2009
- Neurodegeneration and chronic renal failure in methylmalonic aciduria—A pathophysiological approachJournal of Inherited Metabolic Disease, 2007
- Selective screening for inborn errors of metabolism on clinical patients using tandem mass spectrometry in China: A four‐year reportJournal of Inherited Metabolic Disease, 2007
- Combined methylmalonic aciduria and homocystinuria (cblC): Phenotype–genotype correlations and ethnic-specific observationsMolecular Genetics and Metabolism, 2006
- Oral pharmacologic doses of cobalamin may not be as effective as parenteral cobalamin therapy in reversing hyperhomocystinemia and methylmalonic acidemia in apparently normal subjectsClinical and Laboratory Haematology, 2006
- Methylmalonic and propionic aciduriaAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2006
- Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC typeNature Genetics, 2005
- Pathophysiology, diagnosis, and treatment of methylmalonic aciduria?recent advances and new challengesPediatric Nephrology, 2004